Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
EVA Pharma, one of the fastest-growing pharmaceutical companies in the Middle East and Africa (MEA), has recently celebr…
“Those who have worn the HoloLens 2 in the operating room see it as a true game-changer. They have the planning images i…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for inter…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…